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Abstract: 
In recent years, orotidine-5′-monophosphate decarboxylase (ODCase) has gained renewed 
attention as a drug target. As a part of continuing efforts to design novel inhibitors of ODCase, 
we undertook a comprehensive study of potent, structurally diverse ligands of ODCase and 
analyzed their structural interactions in the active site of ODCase. These ligands comprise of 
pyrazole or pyrimidine nucleotides including the mononucleotide derivatives of pyrazofurin, 
barbiturate ribonucleoside, and 5-cyanouridine, as well as, in a computational approach, 1,4-
dihydropyridine-based non-nucleoside inhibitors such as nifedipine and nimodipine. All these 
ligands bind in the active site of ODCase exhibiting distinct interactions paving the way to 
design novel inhibitors against this interesting enzyme. We propose an empirical model for the 
ligand structure for rational modifications in new drug design and potentially new lead 
structures. 
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Article: 
INTRODUCTION 
Orotidine-5′-monophosphate decarboxylase (ODCase) catalyzes the decarboxylation of OMP (1) 
to UMP (2) in the de novo pathway for the transformation of the amino acid, aspartic acid to 
UMP. ODCase has attracted much attention from biochemists because of its status as one of the 
most proficient enzymes in Nature accelerating the rate of decarboxylation by over 17 orders of 
magnitude to produce the key pyrimidine nucleotide, UMP.1,2,3 Pyrimidine nucleotides are 
important building blocks for the synthesis of RNA and DNA, molecules essential for cell 
replication and survival. Due to its important role in the de novo nucleic acid biosynthesis, 
ODCase is present in most species including bacteria, parasites and humans but not in viruses. 
Viruses depend on their host cells for the supply of nucleotides. In humans, pyrimidine 
nucleotides are synthesized via two routes: the de novo and salvage pathways.4 Whenever higher 
concentrations of pyrimidines are needed in the cell, including for the normal cellular processes, 
during uncontrolled growth of the cell such as in cancer, or fast replicating viral infections etc, de 
novo pyrimidine synthesis is upregulated, and the activity of ODCase is simultaneously 
operating at a higher than normal level.5,6 
 
In certain higher-level organisms, such as mouse or human, ODCase is part of the bifunctional 
enzyme, UMP synthase.7 While in pathogenic organisms, such as bacteria, fungi and parasites, 
ODCase is a monofunctional enzyme, although in Plasmodia it forms a heterotetramer with 
orotate phosphoribosyltransferase.8,9,10 In all species, ODCase seems to be active as a dimer and 
the catalytic site is comprised of active residues from the second monomer. Plasmodia such as 
Plasmodium falciparum and Plasmodium vivax are dependent on their own de novo synthesis of 
pyrimidine nucleotides due to their lack of the salvage pathway.11 Thus, inhibition of plasmodial 
ODCase was proposed as a strategy for compounds directed against malaria, and a limited 
number of orotate analogs were investigated as potential drugs against the malaria parasite.12,13,14 
ODCase has also been identified as a potential target for drugs directed against RNA viruses like 
pox and flaviviruses.15,16,17,18 ODCase inhibitors have also been effective against West Nile virus, 
a recent thread to humans and birds in the US and Canada.19 In the recent years, an increased 
interest in ODCase as a drug target is also due to the advances in determining the three-
dimensional structures of this enzyme from various species. Since 2000, when the first X-ray 
structures of ODCase were resolved, there are now almost 100 coordinate sets of ODCase from 
at least 11 different species deposited in the Protein Databank (www.rcsb.org). These crystal 
structures were determined for the apo-form of the protein but mostly in complex with a variety 
of ligands such as UMP (2), 6-aza-UMP (3), BMP (4), XMP (5), CMP (6), as well as with a 
variety of mutant forms of ODCase. Despite such intense efforts in recent years, the catalytic 
mechanism of ODCase is still not completely understood and the use of structure-based tools in 
the rational design of substrate analogs of ODCase as inhibitors is still rudimentary at best. 
 
Recently, investigations on the mechanism of decarboxylation by ODCase have gained 
momentum and there is compelling evidence that a C6 carbanion-based transition-state is formed 
during the decarboxylation.20,21 This transition-state intermediate appears during the early stage 
of the reaction, and electrostatic stress may play a role in the process of decarboxylation, 
although other mechanisms using computational and kinetic isotope methods suggest 
alternatives.20,21,22,23,24 We have recently revealed that under suitable conditions ODCase can 
facilitate interesting reactions other than decarboxylation, such as the transformation of 6-cyano-
UMP (9) into BMP (4).25,26 Based on the catalytic promiscuity exhibited by ODCase, Wittmann 
et al. proposed the possibility of a covalent mechanism as a unifying means of addressing various 
biochemical reactions undertaken by ODCase.27 Our group has disclosed a comprehensive time-
resolved crystallography and mutant analyses on the interactions and catalysis of 9 with 
ODCase.26 The structural evidence in these studies compels us to believe that the slow catalysis 
for the transformation of 9 into 4 represents non-covalent catalysis, involving strong electrostatic 
forces breaking the resonance established in the 6-cyano-pyrimidine nucleic base.26 ODCase also 
exhibits plasticity in accepting various nucleotide ligands including compounds such as XMP (5) 
and in fact these compounds are among the potent inhibitors of this enzyme.28 It is also 
interesting to note that ODCases from various species exhibit different binding affinities towards 
the same inhibitors.27 The new generation of inhibitors such as the novel C6-substituted uridine 
derivatives targeting ODCase specifically are exhibiting interesting and promising therapeutic 
activities.29,30,31 
 
Nucleosides are well established as a major source of drugs for the treatment of cancer and viral 
infections.32,33 A classic example of an unconventional nucleoside of medicinal interest, and a 
potent inhibitor of ODCase is pyrazofurin (also known as pyrazomycin, 7, Fig. 1). This 
compound was originally isolated from the broth filtrates of Streptomyces candidus.34,35 It has 
been the subject of numerous investigations over the past three decades due to its C-nucleoside 
status and its breadth of clinically relevant biological activities.12 Pyrazofurin exhibits potent 
anticancer activity, especially against leukemia cell lines.36,37,38 In clinical trials, pyrazofurin was 
administered to cancer patients at various doses to evaluate its potential as an anticancer agent. 
However, its development was abandoned later due to toxicity.39 Pyrazofurin has also been 
evaluated as an antiviral agent targeting respiratory syncytial virus (RSV), influenza, vaccinia, 
West Nile virus and other RNA viruses.19,40,41,42 Additionally, this compound has been shown to 
be effective against parasitic infections specifically Plasmodium falciparum and also was 
implicated in immunosuppressive therapy.13,43 With such a long history, pyrazofurin as well as 
other pyrazole-based nucleosides are continuing to generate interest in medicinal chemistry.44 
The 5′-monophosphate derivative of pyrazofurin (8) is a potent inhibitor of Saccharomyces 
cerevisiae ODCase with inhibition constants in the low nanomolar range.35  
 
Figure 1: OMP (1), UMP (2), 6-aza-UMP (3), BMP (4), XMP (5), CMP (6), pyrazofurin (7), 
pyrazofurin-5′-monophosphate (8), 6-cyano-UMP and (9) 5-cyano-UMP (10). 
 
 
Due to this exciting and rich biological activity profile at the molecular and clinical levels, our 
group is interested in further characterizing the interactions of pyrazofurin-5′-monophosphate (8) 
and other substrate analogs such as BMP (4), and 5-cyano-UMP (10) along with non-nucleoside 
inhibitors with ODCase to define pharmacophore features for substrate analogs. An empirical 
structural dissection and a pharmacophore model are presented based on the atomic level 
interactions for the potential design of novel classes of compounds targeting ODCase. 
 
EXPERIMENTAL SECTION 
Synthesis 
General. Anhydrous chemical reactions were performed under a nitrogen atmosphere. All 
solvents and reagents were obtained from commercial sources. NMR spectra were recorded on a 
Varian spectrometer (300 or 400 MHz for 1H, and 121.46 MHz for 31P). Chemical shifts are 
reported in ppm using H2O as the reference for the 1H NMR spectra, and phosphoric acid as an 
external standard for the 31P spectra. Mass spectra were obtained on a Q-Star mass spectrometer 
using ESI or EI techniques. The monophosphate derivatives were transformed into the 
corresponding ammonium salts by treatment with 0.5 M NH4OH solution at 0 °C followed by 
lyophilization. Purity of the compounds 8 and 10 was checked on a Waters Delta 660 HPLC 
system attached to a PDA detector, using a Waters ODS2 5 micron reverse phase 
(4.6 × 100 mm) column, was >95%. The eluting system was either 100% H2O or 95% H2O/5% 
MeOH at a flow rate of 0.5 mL/min. All HPLC solvents were filtered through Waters 
membranes (47 mm GHP 0.45 μm, Pall Corporation) and degassed with helium. Injection 
samples were filtered using Waters Acrodisc® Syringe Filters 4 mm PTFE 0.2 μm. 
 
4-Hydroxy-5-(5-O-monophosphoryl-β-d-ribofuranos-1-yl)-1H-pyrazole-3-carboxamide (8). 
Pyrazofurin (7) (11 mg, 0.042 mmol) was dissolved in triethyl phosphate (0.5 mL) and the 
solution was stirred at 45 °C for 10 min under a nitrogen atmosphere. The reaction mixture was 
cooled to 0 °C and POCl3 (23.7 μL, 0.25 mmol) was added and stirring continued at the same 
temperature for an additional 5 h. The reaction was then quenched with cold water (1.5 mL), 
washed with diethyl ether (5 × 2 mL) and neutralized with 0.5 M NH4OH. The volume of the 
aqueous layer was reduced under vacuum, and the crude was purified by HPLC to obtain the 
target compound 8. UV λmax (pH 8) 263 nm (ε = 2,477); 1H NMR (D2O) δ 4.82 (d, J = 5.9 Hz, 
1H, H-1′), 4.26 (br m, 1H, H-2′), 4.13 (br m, 1H, H-3′), 4.04 (br m, 1H, H-4′) 3.93 (br m, 2H, H-
5′); 31P NMR (D2O) δ 0.40 ppm; HRMS (ESI −ve) calculated for C9H13N3O9P (M−): 338.0394, 
found 338.0407. 
 
1-(5-O-t-Butyldimethylsilyl-2,3-O-isopropyl-β-d-ribofuranosyl)-5-cyanouracil (12). 
Compound 1123 (2.6 g, 5.44 mmol) was dissolved in 20 mL of anhydrous DMF and treated with 
NaCN (0.43 g, 8.77 mmol) at 100 °C for 3 h. After this time, the reaction mixture was diluted 
with water (20 mL) and the pH brought to 6; the solution was extracted (3×) with 30 mL of ethyl 
acetate, the organic layer was washed with brine, dried with sodium sulfate, evaporated. 
Purification by column chromatography (hexanes/ethyl acetate, 9:1) gave 12 as a white powder 
(2.21 g, 96%). 1H NMR (CDCl3) δ 0.13 (s, 6H), 0.91 (s, 9H), 1.37 (s, 3H), 1.60 (s, 3H), 3.82 (dd, 
1H, H-5′), 3.98 (dd, 1H, H-5′), 4.53 (m, 1H, H-4′), 4.69 (dd, 1H, H-2′), 4.73 (dd, 1H, H-3′), 5.89 
(d, 1H, H-1′), 8.32 (s, 1H, H-6), 8.96 (broad, 1H, NH). 
 
 
1-β-d-Ribofuranosyl-5-cyanouracil (13). Compound 12 (2.2 g, 5.20 mmol), was treated with 
20 mL of 50% trifluoroacetic acid at 0 °C, and the reaction mixture was stirred at rt for 3 h. After 
this time, solvent was evaporated and the residue was purified by column chromatography 
(dichloromethane/methanol, 8:2) to obtain 13 as a light solid (1.3 g, 93%). UV 
λmax = 278 nm; 1H NMR (CD3OD) δ 3.78 (dd, 1H, H-5′), 3.95 (dd, 1H, H-5′), 4.05 (m,1H, H-4′), 
4.19 (m, 2H, H-2′, H-3′), 5.83 (d, 1H, H-1′), 9.02 (s, 1H, H-6); 13C NMR (CD3OD) 162.15, 
151.25, 150.898, 114.76, 92.17, 90.15, 86.25, 76.47, 70.14, 61.15; HRMS (ESI) calculated for 
C10H12N3O6 (M+H) 270.0720, found 270.0725. 
 
1-(5-Monophosphoryl-β-d-ribofuranos-1-yl)-5-cyanouracil (10). To a solution of water 
(0.05 mL, 2.78 mmol), CH3CN (4.3 mL), pyridine (0.39 mL, 4.8 mmol) and POCl3 (0.612 g, 
0.037 mL, 4 mmol) at 0 °C, were added 0.269 g (0.702 mmol) of compound 13. The reaction 
mixture was stirred for 5 h (3 h at 0 °C and then at room temperature). The reaction was 
monitored by TLC (n-butanol, water and acetic acid, 2:2:1). After the starting material was 
consumed, the reaction was quenched with 2 mL of cold water and stirred for an additional 2 h at 
rt. The solvent was evaporated and then the product was purified by passing through a basic 
Dowex column (eluted with water followed by 5% formic acid). The concentrated product was 
then dissolved in 3 mL of cold water and neutralized with NH4OH. The solvent was evaporated 
and the product was lyophilized to give 0.287 g (yield 75%) of 10 as a white solid. UV 
λmax = 278 nm (ε = 1949); 1H NMR (CD3OD) δ 4.11 (dd, 1H, H-5′), 4.22–4.27 (m, 3H, H-3′, H-
4′, H-5′), 4.33 (dd, 1H, H-2′), 5.86 (d, 1H, H-1′), 8.63 (s, 1H, H-6). 31P (D2O) 0.12 (s), HRMS 
(ESI) calculated for C10H11N3O9P (M−) 348.0227, found 348.0238. 
 
ODCase production 
ODCases from Methanobacterium thermoautotrophicum, Plasmodium falciparum and Homo 
sapiens were cloned, expressed and purified as described previously. [23] and [27] Production and 
purification of the Helicobacter pylori and Staphylococcus aureus enzymes will be described 
elsewhere.45 Enzyme concentrations were determined using a BioRAD protein assay kit with 
bovine serum albumin as standard. 
 
Enzymology 
Assays were performed on a VP-ITC microcalorimeter (MicroCal). For isothermal titration 
calorimetry (ITC) experiments, the initial delay (60 s), stirring speed (300 rpm), reference power 
(15 μcal/s), and the frequency of data point collection (or filter period, 1 s) were identical for all 
experiments. The Hs- and Mt ODCase stock solutions were prepared using 50 mM Tris (pH 7.5), 
20 mM DTT, and 40 mM NaCl, and incubated overnight at rt. For injection into ITC, the 
substrate was dissolved in 50 mM Tris to a final concentration of 5 mM. All inhibitor solutions 
were prepared in the same 50 mM Tris buffer. The assay buffer for the enzyme or 
enzyme/inhibitor samples consisted of 50 mM Tris (pH 7.5) and 1 mM DTT, and was degassed 
prior to use. The activity of Mt ODCase (final concentration 20 nM) was determined at 55 °C. 
Each reaction was initiated by an 11.4 μL injection of substrate solution (5 mM). The final 
substrate concentration in the 1.3 mL calorimetric cell was 40 μM. The activity of Hs ODCase 
(final concentration 60 nM) was determined in the presence of 20 μM substrate at 37 °C, and the 
reaction was initiated by a 5.7 μL injection of substrate solution (5 mM). 
 
Both Mt and Hs ODCases were tested against 5-fluoro-6-amido-UMP (11) in a reversible 
inhibition assay. The final concentration of Mt ODCase was 20 nM while the concentration of 11 
was 0.5, 1, 2.5, and 5 mM. Hs ODCase (60 nM) was exposed to 0.1, 0.25, 0.5, and 1 mM of 11. 
The volume and the final concentration of the substrate were the same as described for the 
controls. The concentrations of compound 8 were 5, 10, 20, and 40 μM against Mt ODCase. The 
inhibition of 60 nM Hp ODCase was determined using 0.25, 0.5, 1, and 1.5 μM of compound 
8.46 
 
5-Cyano-UMP (9) was tested against Pf, Hp and Sa ODCases.44 The final concentration of the Pf 
ODCase and the substrate in the reaction assay was 60 nM and 12 μM, respectively. The 
concentration of the inhibitor was 0.5, 1, 2, 2.5, and 5 mM. The reversible inhibition of Hp 
ODCase (60 nM) was tested in the presence of 0.25, 1, 1.5, and 2.5 mM of 10. The reversible 
inhibition assay with 30 nM Sa ODCase was performed using the following concentrations of 
10: 0.1, 0.25, 0.5, 0.75, and 2 mM. The concentration of the substrate used in the assays with Hp 
and Sa ODCases was 20 μM. 
 
Inhibition kinetics of compound 8 against Hs ODCase were determined using UV spectroscopy. 
The absorption maxima of the ligands permitted a reliable UV-based kinetics assay. Hs ODCase 
stock solution (60 μM) was prepared in 50 mM Tris (pH 7.5), 20 mM DTT, and 40 mM NaCl, 
and incubated overnight at room temperature. Assay samples were prepared by diluting 3 μL of 
the stock enzyme solution in 50 mM Tris containing 1 mM DTT to a final volume of 990 μL. 
Each reaction was initiated by the addition of 10 μL of the ligand (either substrate, or substrate 
mixed with the inhibitor). The final concentrations of Hs ODCase and OMP were 180 nM and 
50 μM, respectively. The concentrations of compound 8 were 1, 1.5, 2, 2.5, 3, and 4 μM. After 
the addition of ligand, the sample was mixed quickly, and the absorption at 285 nM was recorded 
on a Shimadzu UV-2401PC spectrophotometer as a function of time. 
 
The KM values for Hs and Mt ODCases (from ITC measurements) were 1.7 ± 0.1 and 
3.7 ± 0.2 μM, respectively. And the KM for Hs ODCase was 3.4 ± 0.5 μM as determined by UV 
spectroscopy. 
 
Data analysis: The procedure used for the determination of competitive inhibition constants was 
described earlier.47 The data were fitted in Grafit 7.0 to (Eq. (1)) to calculate the Ki for each 
inhibitor. 
 
1:  
 
 
Inhibition of Hs ODCase by8: Compound 8 is a slow tight binding inhibitor of Hs ODCase. The 
rate of consumption of the substrate was converted into the rate of product formation using (Eq. 
(2)): 
 
2: 
 
where vi represents the initial rate and vs is the steady-state rate. The parameter kobs corresponds 
to the rate constant for the conversion from initial to steady-state rate. The initial phase of slow 
and reversible inhibition is represented by (Eq. (3)). 
 
3:  
 
 
The relationship between [I] and kobs is linear, and the data fit to (Eq. (4)) yields the association 
and dissociation constants (k3 and k4): 
 
4:  kobs=k3[I]+k4 
 
The apparent inhibition constant Kiapp is calculated from the ratio of k4/k3. The true inhibitor 
dissociation constant Ki is determined by (Eq. (5)): 
 
5:  
 
 
Crystallization and crystallographic analysis 
All crystals were grown at rt using the hanging-drop method and mixing 2 μL of protein solution 
of 10 mg/mL enzyme in either 25 mM Tris·HCl, pH 8.0, 40 mM NaCl, 5% glycerol for 
complexes of Hs ODCase with compounds 4 and 10 or in 50 mM Tris·HCl, pH 8.5, 100 mM 
NaCl and 5 mM β-mercaptoethanol for compound 8, with 2 μL of the respective reservoir 
solution. The best co-crystals of Hs ODCase with both BMP (4) and 5-cyano-UMP (10) were 
grown in 100 mM Tris·HCl, pH 8.4, 2.12 M ammonium sulfate while the complex with 
compound 8 had the best results in 100 mM Tris·HCl, pH 8.4, 1.4 M ammonium sulfate. The 
crystals with compounds 4 and 8 adopted space group C2221 with unit cell dimensions of 
a = 77.6 Å, b = 116.9 Å, c = 62.0 Å and a = 79.4 Å, b = 116.5 Å, c = 62.1 Å, respectively. 
Crystals of the complex with compound 4 also grew in space group C2221 but with unit cell axes 
a = 77.6 Å, b = 116.9 Å, c = 62.0 Å, whereas the complex with compound 10 grew in space 
group P21 with unit cell dimensions of a = 69.5 Å, b = 61.6 Å, c = 70.9 Å, β = 111.8°. 
 
For data collection, the crystals were either transferred to reservoir solution containing 20% 
glycerol for cryoprotection or dipped into paratone oil before they were flash-frozen in a stream 
of boiling nitrogen. Diffraction data for the crystals of Hs ODCase co-crystallized with 4 were 
collected at 100 K and λ = 0.9002 Å at beam line 14BM-C, BioCARS, Advanced Photon Source, 
Argonne National Laboratories; data for the pyrazofurin-MP (8) and 5-CN-UMP (10) complexes 
were collected at 100 K and λ = 0.97949 Å and λ = 0.97934 Å, respectively, at beam line 08ID-1 
of the Canadian Macromolecular Crystallography Facility, Canadian Light Source. Data were 
reduced and scaled using the program package HKL2000.47 Data collection statistics are given in 
Table 1. 
 
The structures of all complexes were determined using molecular replacement techniques with 
the help of the program package MOLREP48 subsequent refinements were done with Refmac-
5.2,49 and model building with COOT.50 Refinement statistics are also listed in Table 1. Atomic 
coordinates and structure factors have been deposited in the Protein Data Bank (PDB IDs: 
3BGG, 3MI2 and 3BK0 for the complexes with ligands 4, 8 and 10, respectively). 
 
Table 1: Data collection and refinement statistics for the X-ray crystal structures of the ODCase 
complexes of the inhibitors, 4, 8 and 10 
 Hs  
ODCase + 4 
Hs  
ODCase + 8 
Hs  
ODCase + 10 
Diffraction data 
Resolution (Å) 1.93 (1.96–1.93) 1.20 (1.30–1.20) 1.60 (1.66–1.60) 
Measured reflections (n) 149,221 525,889 193,939 
Unique reflections (n) 21,306 78,679 58,529 
Completeness (%) 95.3 (74.6) 87.0 (60.0) 78.5 (21.7) 
Rsym (%) 13.0 (50.0) 2.8 (30.6) 5.8 (32.3) 
Space group C2221 C2221 P21 
Unit cell dimensions (Å) a 77.6 79.4 69.5 
b 116.9 116.5 61.6 
c 62.0 62.1 70.9 
Unit cell angle (°) α, β, χ 90, 90, 90 90, 90, 90 90, 118.9, 90 
Molecules in asymmetric unit (n) 1 1 2 
 Refinement statistics 
Resolution (Å) 50.0–1.93 30.4–1.20 50.0–1.60 
 (1.98–1.93) (1.23–1.20) (1.63–1.60) 
Protein atoms (n) 2,025 2,543 4,167 
Water molecules (n) 132 348 256 
Reflections used for R free (n) 1048 (54) 3965 (166) 2938 (49) 
Rwork (%) 18.1 (25.0) 17.2 (27.3) 17.9 (27.5) 
R free (%) 21.0 (25.3) 18.8 (25.1) 21.6 (33.7) 
Root mean square deviation bond length (Å) 0.010 0.010 0.010 
Root mean square deviation bond angle (°) 1.6 1.5 1.5 
Average B-factor (Å2) 27.1 15.9 22.4 
Numbers in brackets are for the highest resolution shells. R sym = S|I − 〈I〉/σI, where I is the observed intensity and 〈I〉 is the average 
intensity from multiple observations of symmetry-related reflections. 
 
Computer modeling 
The three-dimensional structure of the Hs ODCase complex with 6-NH2-UMP (PDB code: 
3DBP) was used as the protein framework for the docking study. The ligand and the 
crystallographic waters were removed from the active site, and hydrogens were added to the 
entire protein, preparing the active site for docking. The non-nucleoside ligands, nifedipine and 
nimodipine were docked using Surflex-Dock, a module in the SYBYL molecular modeling 
package, for various docking poses and their relative ranking. This process involves first, the 
active site was coated with three types of probes, depending on the properties of the enzyme 
residues exposed into the active site: CH4 for steric, N–H for HB donor, C O for HB acceptor. 
Then the ligand fragments were generated and posed into binding site to generate the best fitting 
pose for the ligand. The Hammerhead, a completely automatic, fast docking procedure was used 
to dock these two compounds to binding site. The top ranking conformation of the ligand in the 
binding pocket was used to analyze the interactions. 
 
For ligand conformational analysis, eleven co-crystal structures of ODCase with eleven ligands 
were collected, and the inhibitors were extracted from the corresponding active sites. These 
structures include UMP (1DBT), 6-aza-UMP (1DVJ), 5-I-UMP (2QCH), BMP (1X1Z), 6-NH2-
UMP (2Q8Z), 5-Br-UMP (2QCG), 5-CN-UMP (3BKO), 5-F-UMP (2QCF), 6-acetyl-UMP 
(3L0K), 6-I-UMP (covalent complex, 3BGJ) and OMP (1KM6). 
 
 
 
RESULTS AND DISCUSSION 
In this study, the overarching goal is to bring together structurally diverse but potent ligands of 
ODCase and investigate their interactions with the active site of ODCase. As mentioned above, 
first we focused on three structurally diverse nucleoside ligands of ODCase. BMP (4), one of the 
ligands included in this study, carries a hydroxyl moiety at the C6 position and is the most potent 
inhibitor of ODCase with a Ki of 8.8 × 10−12 M for the yeast enzyme.51 Both the C6 hydroxyl 
moiety in 4 and the C4 substitution in 8 are similar in their location and their ability to present 
the anionic moiety for transition-state mimicry. Pyrazofurin-5′-monophosphate (8) is a C-
nucleoside carrying a pyrazole moiety instead of the pyrimidine nucleic base, and does not 
possess the typical glycosidic bond similar to the natural N-nucleoside. In fact pyrazofurin (7) 
was one of the very few C-nucleosides evaluated clinically as an anticancer and antiviral agent.12 
The corresponding mononucleotide 8 binds tightly at the active site of ODCase, thus this 
compound was of great interest to us and we investigated its interactions with the protein matrix 
in greater detail. Structurally, the presence of cyano substituent at the C5 position of compound 
10 was not only intended to provide clues on the interactions of the 5-CN moiety with ODCase, 
but also test whether any unusual chemistry could be observed as had been the case with 6-CN-
UMP. [23] and [24] 
 
Compound 4 was synthesized according to the reported procedure.52 The mononucleotide 
derivatives of 8, and 10 were synthesized according to Scheme 1. Compound 10 was synthesized 
from the fully protected 5-bromouracil derivative 11 by treatment with sodium cyanide to obtain 
compound 12 followed by deprotection with aqueous TFA to give 13 (Scheme 1A). 5-
Cyanouridine (13) was phosphorylated by treatment with POCl3 to yield 10. Pyrazofurin (7) was 
phosphorylated using triethyl phosphate and POCl3 to obtain compound 8 (Scheme 1B). For 
enzymatic studies, Hs, Mt, Sa, Pf and Hp ODCase, that is, enzymes from species spanning higher 
organisms, Archaea and bacteria were employed. Compounds 4, 8 and 10 were co-crystallized 
with Hs ODCase and the corresponding three-dimensional structures were determined to detail 
the atomic interactions in the binding site of Hs ODCase (1.93, 1.2 and 1.6 Å resolution, 
respectively, Fig. 2). 
 
 
Scheme 1: Synthesis of compound 8 and 10. 
 
 
 
Figure 2: The active sites of ODCase as seen in the co-crystal structures of the complexes of 8 
(panels A and B), 10 (panels C and D), and 4 (panels E and F) with Hs ODCase. Panels B, D and 
F depict the electron densities (2Fo − Fc) corresponding to the inhibitor molecules, displayed at 
1σ level. Enzyme backbones are rendered according to their secondary structures, and the ligands 
are shown in capped-stick representation. 
 
 
 
The active site architectures for the ODCase complexes with 4, 8 and 10 are almost identical, and 
there are no major differences in the conformations of the residues that comprise the active site. 
An analysis of the hydrogen-bonding network, however, allows one to identify the similarities 
and differences for the different ligands (Fig. 3). The phosphoribosyl moiety in all three 
inhibitors exhibited very similar interactions with the enzyme. This portion of the nucleotide 
engages in a network of hydrogen-bonding interactions, primarily through the 2′ and 3′ hydroxyl 
moieties as well as the phosphoryl moiety at the 5′-position. This is a typical feature found in the 
other inhibitor complexes of ODCase and this interaction is responsible for a large contribution 
towards the binding energy.53,54 
 
Figure 3: Schematic of the interactions of 8, 10 and 4 with the active site of Hs ODCase (panels 
A, B and C, respectively). 
 
 
In the active site of ODCase, BMP (4) positions its highly acidic hydroxyl moiety at C6 close to 
the side chains of Lys125 and Asp123, which are both part of a strong network of ionic bonding 
interactions (Fig. 2E,F, and Fig. 3C). Close by, the presence of a tightly bound water molecule 
(2.75 Å distance from 6-OH moiety) correlates well with BMP binding, probably mitigating the 
potency of BMP to interact with ODCase (Fig. 3C). 5-Cyano-UMP on the other hand does not 
carry any C6 substitution but a neutral cyano group at the C5 position that fits well into a small 
hydrophobic pocket in the active site. The remaining parts of the respective nucleic base of 4 and 
10 interact with the ODCase active site in very similar fashion, mostly through conserved 
hydrogen bonds. For example, the O2, N3 and O4 atoms in 4 and 10 exhibit almost identical 
interactions with the side chains of Gln241, Ser183 and a crystallographic water molecule (Fig. 
3B and C). At physiological pH, the hydroxyl moiety is deprotonated and presents compound 4 
as a transition-state analog, a feature described earlier.3,20,21 
 
The C-Nucleoside analog pyrazofurin (7) and its monophosphate derivative 8 are 
pharmacologically well-characterized compounds. Little is known, however, of 8’s interactions 
with its target enzyme ODCase. Pyrazofurin does not have the typical glycosidic bond present in 
N-nucleosides (Fig. 4). The pyrazole moiety is attached via the C5 carbon to the C1′ position of 
the ribosyl moiety, and in addition, carries two key substitutions on the pyrazole moiety: an 
amido moiety at C3 and a hydroxyl moiety at C4 position (Fig. 4). This hydroxyl moiety (pKa 
6.7) would be deprotonated to a large extent at physiological pH (7.4), similar to what is found 
with BMP (4). It is anticipated that the hydroxyl moiety could mimic the transition-state species, 
again similar to BMP, when bound to the active site of ODCase. Thus we co-crystallized 
pyrazofurin-5′-monophosphate (8) with Hs ODCase and determined the three-dimensional 
structure of the complex at 1.2 Å resolution (Table 1, Fig. 2A,B, and Fig. 3A). The aza-moiety in 
the pyrazole ring of 8 interacts via hydrogen bonds with the side chains of Gln241 and Ser183 
(Fig. 3A). These hydrogen bonds account for the interactions of O2 and N3 in a typical 
pyrimidine nucleic base (Fig. 3A vs C). The carbonyl moiety in the C3 amido group of the 
pyrazole ring interacts with the backbone nitrogen of Ser183 and a water molecule, equivalent to 
the interactions of the O4 moiety in the natural uracil ring. This pattern of strong interactions 
locks the orientation of the pyrazole moiety in the ODCase binding site presenting other 
functional groups to the conserved catalytic residues (Fig. 2A). 
 
The second set of interactions of the pyrazole moiety includes the salt bridge between the ionized 
hydroxyl group linked to C4 and the positively charged side chain of Lys125 as well as two 
hydrogen bonds with bound water molecules (d = 2.6–2.9 Å). Although these interactions of the 
pyrazole moiety in 8 are not identical to those seen with the pyrimidine nucleic base in 4, 
equivalent electrostatic and steric interactions nevertheless result in tight binding of 8 to ODCase 
(Fig. 3A vs C). Our results assert that the heterocycle on the ribose can be varied without 
compromising binding affinity; in this particular case, pyrimidine and pyrazole provided the 
same ‘backbone’ environment to the ligand structure. Purine heterocycles can also be substituted, 
as recently reported for xanthosine-5′-monophosphate (5, Fig. 1), another highly potent inhibitor 
of ODCase.27 Even molecules like nifedipine and nimodipine (14 and 15, respectively, Fig. 4), 
clinically used calcium channel blockers, inhibit ODCase competitively, with inhibition 
constants (Ki) of 105 and 18 μM, respectively.55 These observations contribute to the mounting 
evidence that ODCase, although evolved to carry out the decarboxylation of OMP with high 
efficiency, is inherently promiscuous in binding to other nucleosides, both purines and 
pyrimidines, as well as to non-nucleoside inhibitors. 
 
Figure 4: Structures of nucleoside and non-nucleoside inhibitors of ODCase. 
 
 
 
Compounds 8 and 10 were also evaluated for their potential to inhibit ODCases from P. 
falciparum, H. pylori, M. thermoautotrophicum, H. sapiens and S. aureus (Fig. 6 and Table 2). 
The 5-cyanouridine derivative 10 inhibited Pf, Hp and Sa ODCases with very weak inhibition 
constants (Ki) of 0.91 ± 0.03, 0.29 ± 0.01 and 0.55 ± 0.007 M, respectively, similar to its 
inhibition of Hs and Mt ODCases (Ki = 0.14 ± 0.06 and 0.70 ± 0.02 M, respectively). These poor 
inhibitory properties also reflect the weak molecular interactions between the 5-cyanouridine 
derivative 10 and ODCase (Fig. 3B). On the other hand, compound 8 inhibited Hs- and Mt 
ODCases following two distinct mechanisms. While it is a competitive inhibitor for Mt ODCase 
with a Ki of 6.2 ± 0.6 μM, it interacts with Hs ODCase with a kinetics profile akin to that of a 
slow, tight binding inhibitor (Table 2). For Hs ODCase, the inhibition constant Ki was estimated 
at 17 nM, about three orders of magnitude better than the one for Mt ODCase, but similar to that 
found for yeast ODCase (Table 2).35 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Lineweaver-Burk reciprocal plots to determine the reversible inhibition constant Ki for 
8 with Mt ODCase (panel A). Panel B depicts the plot of kobs as a function of [8] with Hs 
ODCase, and the inset in this panel shows the progress curves of the ODCase reaction in the 
presence of various concentrations of 8. 
 
 
 
Table 2: Inhibition kinetics for compounds 4, 8, and 10 against Hs-, Mt-, Pf-, Hp-, Sa-, and 
ScODCases 
Enzyme 
K i (mM) 
4 8 10 
HsODCase — 1.7 × 10−5 — 
Mt ODCase — 6.2 ± 0.6 × 10−3 — 
Pf ODCase — — 9.1 ± 0.3 × 102 
Hp ODCase — 1.3 ± 0.6 × 10−4 2.9 ± 0.1 × 102 
Sa ODCase — — 5.5 ± 0.07 × 102 
Sc ODCase35 9 × 10−9 5 × 10−6 — 
 
Enzyme inhibition patterns and inhibition constants coupled to the structural interactions of 4 
and 8 with ODCase imply that these compounds are close mimics of the presumed transition-
state of the decarboxylation reaction catalyzed by ODCase.1 It is highly probable that deviations 
from these molecular structures when designing new inhibitors would compromise the binding 
affinities towards ODCase. This should, however, not be viewed as a negative feature because 
tighter binding to the enzyme does not necessarily imply higher potency at the cellular level or a 
better in vivo efficacy. These latter features are virtues due to physicochemical and 
biopharmaceutical properties associated with individual inhibitors. This is clearly evident in this 
set of compounds; despite its three orders of magnitude weaker affinity when compared to 4, 
compound 8 nevertheless exhibited good therapeutic potential, which led to the evaluation of 
compound 7 in phase I clinical trials.56,12 
 
Dissection of the ODCase ligand structure. Using the information from the above complexes, 
and several other three-dimensional structures of ODCases with nucleotide inhibitors, an 
empirical dissection of the ligand structure is presented in Figure 5. There are three critical 
regions in the binding site, to which these inhibitors appeal to, especially the nucleoside 
derivatives. Region A (highlighted in red) may be important in properly orienting the nucleic 
base moiety. The size and electronic characteristics of the substitutions in region B (in green, 
Fig. 5) will influence potency and the overall inhibitory characteristics of the ligand. For 
example, iodo- and azido-substitutions replacing the carboxyl moiety in OMP (1) result in 
formation of a covalent bond to a lysine residue, and a nitrile moiety at the C6 position of UMP 
(2) is catalytically converted into BMP (4), a very potent inhibitor of ODCase.23,27,26 As seen in 
the co-crystal structure of compound 10 and Hs ODCase, the 5-cyano group on the ligand closely 
fills a hydrophobic pocket, as was also seen with other 5-substitutions such as in 5-fluoro-
UMP.25,57 Interestingly, the presence of a 5-fluoro moiety when combined with a 6-amido group 
(data not shown here) did not favor the inhibition of ODCase but produced one of the least 
potent compounds thus far.23,26,28 It is also interesting to note that ODCase exhibits structural 
plasticity in its interactions with the C5 and C6 positions of region B of the pyrimidine 
moiety.25,28 One thus could incorporate a variety of small to medium size substitutions in region 
B of the ligand. 
 
Figure 5: Empirical structure of a proposed pharmacophore for the ligands in the active site of 
ODCase. 
 
 
The third region, region C (in blue, Fig. 5), especially the 5′-monophosphate moiety, is 
responsible for maintaining the tight binding of the inhibitor to the active site and defines the 
minimal characteristics essential for effective binding to this active site and directing the rest of 
the ligand into the binding site of ODCase. The importance of the monophosphate moiety for 
ligand binding has been eloquently discussed by others and its contributions towards the binding 
energy estimated to be as high as 11 kcal/mol.1 Such large contributions from a remote and non-
reacting phosphoryl group also play an important role for catalysis in other enzymes, for 
example, triose phosphate isomerase, and such an effect is not unique to ODCase.58 Thus anionic 
charges located in region C on the ligand, either due to a phosphate moiety or other anionic 
groups as part of unrelated structural features, possibly discovered through lead hopping, should 
convey high affinity to potential inhibitors. This will provide an opportunity for novel inhibitor 
design, with the potential of steering the core structure away from ‘nucleoside’-like compounds. 
 
Interestingly, as briefly mentioned above, two widely prescribed calcium channel blockers, 
nifedipine and nimodipine are also moderately potent inhibitors of ODCase with Ki values of 
105 and 18 μM, respectively.53 It is quite intriguing to discover that non-nucleoside compounds 
can compete for the same binding site on ODCase as the natural nucleotide substrate(s). Our 
experiments to obtain crystals of ODCase complexes of the channel blockers did not succeed, 
thus we conducted comprehensive computational docking experiments to better understand how 
these non-nucleosides might bind in the active site of ODCase (Fig. 7). Both compounds fit well 
into the active site of ODCase, and interestingly the nitro moiety on the phenyl group interacts 
with the cationic Arg262 (this residue also anchors the monophosphate group in nucleotide 
ligands which is a major contributor to the ligands’ binding energy). The two cyclic moieties in 
both nifedipine (14) and nimodipine (15) span the interior of the active site, an area with which 
nucleoside substrates typically do not interact. The side chains, methoxycarbonyl and 
methoxyethoxycarbonyl moieties on the dihydropyridine of 14 and 15, respectively, bind at the 
hydrophobic site where C-5 substitutions of nucleoside ligands interact. The carbonyl moiety on 
these side chains interacts with Gln241 and Gly229. These docked models reinforce the idea that 
one can achieve ODCase inhibition via structural features other than those of nucleosides. 
 
Figure 7: Stereo view of the active site of Hs ODCase with docked nifedipine (panel A) and 
nimodipine (panel B). The ligand is shown in a ball-and-stick representation and the residues of 
the enzyme are displayed by a capped-tick model; atoms are color-coded according to atom type. 
The backbone of the enzyme is rendered according to secondary structure, and a portion of the 
active site is rendered using a Connolly surface with lipophilic character. A potential hydrogen-
bonding network is shown by dashed lines in orange. 
 
 
In order to ascertain the conformational preferences and the binding mode of nucleotide analogs, 
we undertook an analysis of co-crystal structures of eleven inhibitors bound in the active site of 
ODCase (Fig. 8). Briefly, the bound ligands were extracted from the active site of ODCase and 
were overlapped at three atoms: N1, C1′ and C4′ in order to compare their bound conformations. 
Predominately these molecules assumed 2′-endo/3′-exo conformation and indicated little 
influence onto the proposed pharmacophore model (Fig. 5). We note here that there are 
exceptions to this generality, and we revealed through a comprehensive analysis that nucleotides 
such as CMP and XMP assume diverse conformations.28 Currently there is little experimental 
and/or theoretical evidence to draw conclusions on the unbound conformations of the nucleotides 
and their binding preferences to ODCase, which are also the limitations of the current study. 
 
Figure 8: Overlap of eleven ligands bound in the active site of ODCase, obtained from the 
corresponding co-crystal structures. All inhibitors are shown in capped-stick representation: 
blue: UMP, cyan: 6-aza-UMP, green: 5-I-UMP, greenblue: BMP, magenta: 6-NH2-UMP, 
orange: 5-Br-UMP, purple: 5-CN-UMP, red: OMP, red–orange: 5-F-UMP, violet: 6-acetyl-
UMP, yellow: 6-I-UMP. 
 
 
The generic pharmacophore proposed in Figure 5 although was based on nucleotide ligands, 
above described two non-nucleosides do indeed follow the regions B and C for their interactions 
with ODCase. Therefore, the dissection of the structural determinants for the binding of ligands 
to ODCase presented here will aid in the design of novel nucleoside as well as non-nucleoside 
inhibitors. In summary, we present a comprehensive analysis of structurally diverse ligands 
against ODCase generating an empirical set of principles for ligand interactions. These principles 
are applicable for the design of new generation of inhibitors targeting ODCase. 
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